Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Innovative Funding Models for Alzheimer's Disease & Dementia Research

One of the many highlights of our Alzheimer's Disease Summit: The Path to 2025, was the panel discussion focused on new and innovative funding models. Watch video highlights from that talk.

Published December 02, 2013

Innovative Funding Models for Alzheimer's Disease & Dementia Research

On November 6 and 7, global leaders from government, academia, NGOs, finance, and industry gathered to accelerate progress on Alzheimer's R&D at the "

Program

Alzheimer's Disease and Dementia Initiative

The Academy's Alzheimer's Disease and Dementia Initiative (ADDI) aims to accelerate T1 translation — the transfer of basic research about disease mechanisms into the development of new methods for diagnosis, treatment, and prevention — through an unprecedented multi-sector partnership focused on Alzheimer's disease and dementia.

Archived Event Information

Alzheimer's Disease Summit: The Path to 2025

November 6 - 7, 2013
A primary goal of this critical meeting was to convene leading industry, academic, and government stakeholders to actively participate in discussions regarding how to prevent and effectively treat Alzheimer's by 2025, by coordinating with governmental efforts to build research resources, reengineer current drug development and evaluation systems, and identify innovative technologies and financing models.